Back to Authors

Francis, Jasmine H

0000-0002-7637-3108

Mayo Clinic

Ophthalmic Oncology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.

Citations 2

Long-term outcomes with single-agent BRAF inhibitor therapy in Erdheim-Chester disease

Blood | March 7, 2025 | Volume: 145 | Issue: 18 | Pages: 2100-2103

10.1182/blood.2024028032 | PMID 40053897

Abstract Among 64 patients with Erdheim-Chester disease treated with a BRAF inhibitor (median follow-up 4 years), we found high response rates (85%) but frequent discontinuations (61%), primarily because of adverse events. Additionally, patients experienced poor health-related quality of life and high symptom burden.
Proceedings of the Association for Research in Vision and Ophthalmology and Champalimaud Foundation Ocular Oncogenesis and Oncology Conference

Translational Vision Science & Technology | January 10, 2019 | Volume: 8 | Issue: 1 | Pages: 9

10.1167/tvst.8.1.9 | PMID 30652059